PL3723760T3 - Jednoetapowy sposób mielenia w celu wytworzenia zmikronizowanych estrów paliperydonu - Google Patents

Jednoetapowy sposób mielenia w celu wytworzenia zmikronizowanych estrów paliperydonu

Info

Publication number
PL3723760T3
PL3723760T3 PL18889552.8T PL18889552T PL3723760T3 PL 3723760 T3 PL3723760 T3 PL 3723760T3 PL 18889552 T PL18889552 T PL 18889552T PL 3723760 T3 PL3723760 T3 PL 3723760T3
Authority
PL
Poland
Prior art keywords
milling process
step milling
preparing micronized
paliperidone esters
micronized paliperidone
Prior art date
Application number
PL18889552.8T
Other languages
English (en)
Inventor
Williams SANDERS
Demin Liu
Baohua Yue
Original Assignee
SpecGx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpecGx LLC filed Critical SpecGx LLC
Publication of PL3723760T3 publication Critical patent/PL3723760T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B02CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02CCRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/16Mills in which a fixed container houses stirring means tumbling the charge
    • B02C17/168Mills in which a fixed container houses stirring means tumbling the charge with a basket media milling device arranged in or on the container, involving therein a circulatory flow of the material to be milled

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL18889552.8T 2017-12-14 2018-12-13 Jednoetapowy sposób mielenia w celu wytworzenia zmikronizowanych estrów paliperydonu PL3723760T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762598827P 2017-12-14 2017-12-14
PCT/US2018/065443 WO2019118722A1 (en) 2017-12-14 2018-12-13 One step milling process for preparing micronized paliperidone esters

Publications (1)

Publication Number Publication Date
PL3723760T3 true PL3723760T3 (pl) 2025-10-20

Family

ID=66815477

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18889552.8T PL3723760T3 (pl) 2017-12-14 2018-12-13 Jednoetapowy sposób mielenia w celu wytworzenia zmikronizowanych estrów paliperydonu

Country Status (12)

Country Link
US (1) US20190183896A1 (pl)
EP (1) EP3723760B1 (pl)
JP (1) JP2021506757A (pl)
AU (1) AU2018383636B2 (pl)
CA (1) CA3084002A1 (pl)
DK (1) DK3723760T3 (pl)
ES (1) ES3037855T3 (pl)
HU (1) HUE073135T2 (pl)
MX (1) MX2020005816A (pl)
PL (1) PL3723760T3 (pl)
PT (1) PT3723760T (pl)
WO (1) WO2019118722A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213286A1 (en) * 2018-05-02 2019-11-07 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone
CN110279659A (zh) * 2019-07-08 2019-09-27 华裕(无锡)制药有限公司 棕榈酸帕利哌酮制剂及其制备方法
PL4025187T3 (pl) 2020-11-30 2024-04-29 Janssen Pharmaceutica Nv Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu
EP4025189B1 (en) 2020-11-30 2024-06-05 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
WO2022111859A1 (en) * 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
US12472184B2 (en) 2021-08-20 2025-11-18 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
US20230085549A1 (en) * 2021-08-30 2023-03-16 Janssen Pharmaceutica Nv Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994041A (en) * 1985-04-06 1999-11-30 Eastman Kodak Company Process for buffering concentrated aqueous slurries
US5902711A (en) * 1997-06-25 1999-05-11 Eastman Kodak Company Method to media mill particles using crosslinked polymer media and organic solvent
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
DE60105023T2 (de) * 2000-06-28 2005-08-18 Smithkline Beecham P.L.C., Brentford Nassvermahlungsverfahren
WO2016157061A1 (en) * 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
CA3014788A1 (en) * 2016-02-17 2017-08-24 Alkermes Pharma Ireland Limited Compositions of multiple aripiprazole prodrugs
CN106137985B (zh) * 2016-08-04 2019-03-08 齐鲁制药有限公司 一种稳定的棕榈酸帕利哌酮长效制剂

Also Published As

Publication number Publication date
WO2019118722A1 (en) 2019-06-20
AU2018383636A1 (en) 2020-06-18
BR112020011614A2 (pt) 2020-12-08
PT3723760T (pt) 2025-08-05
AU2018383636B2 (en) 2024-01-18
EP3723760A4 (en) 2021-10-13
MX2020005816A (es) 2020-08-20
JP2021506757A (ja) 2021-02-22
EP3723760A1 (en) 2020-10-21
US20190183896A1 (en) 2019-06-20
DK3723760T3 (da) 2025-08-25
HUE073135T2 (hu) 2026-01-28
ES3037855T3 (en) 2025-10-08
EP3723760B1 (en) 2025-06-11
CA3084002A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
PT3723760T (pt) Processo de moagem de um só passo para preparar ésteres de paliperidona micronizados
EP3693366B8 (en) Processes for preparing ask1 inhibitors
EP3325443A4 (en) PROCESS FOR THE PREPARATION OF PRIDOPIDINE
GB201403356D0 (en) A process for preparing a nicotine-containing formulation
ZA201708142B (en) Process for preparing 4-amino-pyridazines
IL267508B (en) A process for the preparation of 2-pyridylethyl carboxamide derivatives
EP3182964A4 (en) Processes for preparing multiple capsules
ZA201503540B (en) Process for preparing polycyclic carbamoyl pyridone derivatives
GB2531940B (en) Process for preparing methotrexate formulation
SG11201911164WA (en) Method for preparing intermediate of 4-methoxypyrrole derivative
EP3224369A4 (en) Milling process
GB2561497B (en) A process for preparing a solid dispersion of decoquinate
HUE061031T2 (hu) Õrlési eljárás
IL253877A0 (en) Process for preparing 3-chloro-2-vinylphenylsulfonates
ZA201903463B (en) Method for preparing hexadecahydropyrene
EP3177610A4 (en) Process for the preparation of polymorphic forms of nilotinib
EP3118194A4 (en) Method for producing 2-acyliminopyridine derivative
EP3154951A4 (en) Process for preparing quinazoline derivative
ZA201801650B (en) Process for producing novel 4-benzoazonine derivatives
PL3655459T3 (pl) Sposób wytwarzania poliestrów
IL273639A (en) A process for the preparation of pyrrolidine alpha-carboxamide derivatives
EP3181545A4 (en) Method for producing triphenylbutene derivative
EP3124469A4 (en) Process for producing 1-arylimino-2-vinylcyclopropanecarboxylic acid derivative
EP3208267A4 (en) Method for preparing isobenzofuran-1(3h)-one compound
GB201503206D0 (en) Process for making esters